SG10201900451SA - Pharmaceutical formulation containing improved antibody molecules - Google Patents

Pharmaceutical formulation containing improved antibody molecules

Info

Publication number
SG10201900451SA
SG10201900451SA SG10201900451SA SG10201900451SA SG10201900451SA SG 10201900451S A SG10201900451S A SG 10201900451SA SG 10201900451S A SG10201900451S A SG 10201900451SA SG 10201900451S A SG10201900451S A SG 10201900451SA SG 10201900451S A SG10201900451S A SG 10201900451SA
Authority
SG
Singapore
Prior art keywords
antibody molecules
present
pharmaceutical formulation
formulation containing
containing improved
Prior art date
Application number
SG10201900451SA
Inventor
Tomoyuki Igawa
Shinya Ishii
Atsuhiko Maeda
Mika Sakurai
Tetsuo Kojima
Tatsuhiko Tachibana
Hirotake Shiraiwa
Hiroyuki Tsunoda
Yoshinobu Higuchi
Chifumi Moriyama
Akira Hayasaka
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of SG10201900451SA publication Critical patent/SG10201900451SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

TITLE: PHARMACEUTICAL FORMULATION CONTAINING IMPROVED ANTIBODY MOLECULES An objective of the present invention is to provide pharmaceutical formulations containing improved antibody molecules. The present invention provides pharmaceutical formulations comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. Present formulations contain preferably arginine as stabilizer and are provided in liquid or solid form. Fig. 18
SG10201900451SA 2009-03-19 2010-03-19 Pharmaceutical formulation containing improved antibody molecules SG10201900451SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009069095 2009-03-19

Publications (1)

Publication Number Publication Date
SG10201900451SA true SG10201900451SA (en) 2019-02-27

Family

ID=42739479

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201900451SA SG10201900451SA (en) 2009-03-19 2010-03-19 Pharmaceutical formulation containing improved antibody molecules
SG10201703707YA SG10201703707YA (en) 2009-03-19 2010-03-19 Pharmaceutical formulation containing improved antibody molecules
SG2011066768A SG174428A1 (en) 2009-03-19 2010-03-19 Pharmaceutical formulation containing improved antibody molecules

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10201703707YA SG10201703707YA (en) 2009-03-19 2010-03-19 Pharmaceutical formulation containing improved antibody molecules
SG2011066768A SG174428A1 (en) 2009-03-19 2010-03-19 Pharmaceutical formulation containing improved antibody molecules

Country Status (8)

Country Link
JP (2) JP4885308B2 (en)
KR (1) KR101468271B1 (en)
AR (1) AR075908A1 (en)
AU (1) AU2010225951B2 (en)
RU (1) RU2565809C2 (en)
SG (3) SG10201900451SA (en)
TW (1) TWI440470B (en)
WO (1) WO2010106812A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007114319A1 (en) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha Method for control of blood kinetics of antibody
RU2510400C9 (en) 2007-09-26 2014-07-20 Чугаи Сейяку Кабусики Кайся Modification method of isoelectric point of antibody by means of amino-acid replacements in cdr
CN102056946A (en) 2008-04-11 2011-05-11 中外制药株式会社 Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI440469B (en) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JO3417B1 (en) * 2010-01-08 2019-10-20 Regeneron Pharma Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
TWI505838B (en) 2010-01-20 2015-11-01 Chugai Pharmaceutical Co Ltd Stabilized antibody
BR112012022917A2 (en) 2010-03-11 2017-01-10 Pfizer ph-dependent antigen binding antibodies
KR102116202B1 (en) 2010-11-08 2020-05-28 제넨테크, 인크. Subcutaneously administered anti-il-6 receptor antibody
KR102568454B1 (en) 2010-11-30 2023-08-18 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
EP3539991A1 (en) * 2011-01-07 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Method for improving physical properties of antibody
SG10201609665PA (en) * 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
WO2012132067A1 (en) * 2011-03-30 2012-10-04 中外製薬株式会社 Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
UY34105A (en) 2011-06-03 2012-07-31 Lg Life Sciences Ltd STABLE LIQUID FORMULATION OF ETANERCEPT
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TWI589299B (en) 2011-10-11 2017-07-01 再生元醫藥公司 Compositions for the treatment of rheumatoid arthritis and methods of using same
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
US20150056182A1 (en) 2011-11-30 2015-02-26 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
US20160340730A1 (en) * 2013-12-20 2016-11-24 Diogenix, Inc. Methods for evaluating neurological disease
CA3233584A1 (en) * 2013-12-27 2015-07-02 Chugai Seiyaku Kabushiki Kaisha Method for purifying antibody having low isoelectric point
KR101892883B1 (en) 2015-02-27 2018-10-05 추가이 세이야쿠 가부시키가이샤 Composition for treating il-6-related diseases
WO2016190263A1 (en) 2015-05-22 2016-12-01 アステラス製薬株式会社 NOVEL ANTI-HUMAN NGF ANTIBODY Fab FRAGMENT
SG11201805123XA (en) 2015-12-18 2018-07-30 Astellas Pharma Inc Pharmaceutical composition comprising anti-human tslp receptor antibody
CN109862880A (en) * 2016-09-27 2019-06-07 德国费森尤斯卡比有限公司 Composition of liquid medicine
WO2018158332A1 (en) * 2017-03-01 2018-09-07 Medimmune Limited Formulations of monoclonal antibodies
WO2018203545A1 (en) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Method for predicting and evaluating therapeutic effect in diseases related to il-6 and neutrophils
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
JP2021504482A (en) * 2017-11-30 2021-02-15 バイオ−テラ ソリュ−ションズ，エルティーディー． Liquid formulation of humanized antibody for the treatment of IL-6 related diseases
EP3747469A4 (en) 2018-01-31 2022-03-23 Motokazu Kato Therapeutic agent for asthma containing il-6 inhibitor
JP2022502350A (en) 2018-08-29 2022-01-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. Methods and Compositions for Treating Subjects with Rheumatoid Arthritis
US11498969B2 (en) 2019-01-31 2022-11-15 Sanofi Biotechnology Compositions and methods for treating juvenile idiopathic arthritis
AU2020255449A1 (en) 2019-03-29 2021-10-07 Chugai Seiyaku Kabushiki Kaisha Anti IL-6 receptor antibody-containing inhibitor for inhibiting deterioration of BBB function
MX2021012163A (en) 2019-04-17 2022-01-31 Univ Hiroshima Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination.
KR20230017222A (en) 2020-05-29 2023-02-03 추가이 세이야쿠 가부시키가이샤 antibody-containing formulations
KR20220028972A (en) * 2020-08-31 2022-03-08 (주)셀트리온 Stable Pharmaceutical Formulation
JPWO2022191306A1 (en) 2021-03-12 2022-09-15

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL199659B1 (en) * 1998-02-25 2008-10-31 Merck Patent Gmbh Antibody-based fusion protein featured by prolonged residence in a cireculatory system and method of prolonging its residence time in a circulatory system
MXPA04004671A (en) * 2001-11-14 2005-08-25 Johnson & Johnson Anti-il-6 antibodies, compositions, methods and uses.
DK1475101T3 (en) * 2002-02-14 2011-01-10 Chugai Pharmaceutical Co Ltd Antibody-containing pharmaceutical solutions
PT1562972E (en) * 2002-10-15 2010-11-10 Facet Biotech Corp Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
CA2517310C (en) * 2003-02-28 2015-11-24 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations comprising a poloxamer
CN1798767B (en) * 2003-04-10 2011-02-16 晶面生物技术公司 Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
ES2341461T5 (en) * 2004-02-11 2014-10-29 Warner-Lambert Company Llc Procedures for treating osteoarthritis with ANTI-IL-6 antibodies
JO3000B1 (en) * 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
US9084777B2 (en) * 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
JP2009525986A (en) * 2006-02-03 2009-07-16 メディミューン，エルエルシー Protein preparation
WO2007114319A1 (en) * 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha Method for control of blood kinetics of antibody
CA2652976C (en) * 2006-06-02 2015-08-11 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human il-6 receptor
TWI464262B (en) * 2007-09-26 2014-12-11 中外製藥股份有限公司 Antibody constant region mutant
RU2510400C9 (en) * 2007-09-26 2014-07-20 Чугаи Сейяку Кабусики Кайся Modification method of isoelectric point of antibody by means of amino-acid replacements in cdr
MX2010003329A (en) * 2007-09-26 2010-04-27 Chugai Pharmaceutical Co Ltd Anti-il-6 receptor antibody.
CN102056946A (en) * 2008-04-11 2011-05-11 中外制药株式会社 Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly

Also Published As

Publication number Publication date
WO2010106812A1 (en) 2010-09-23
TW201100100A (en) 2011-01-01
RU2011142184A (en) 2013-04-27
KR101468271B1 (en) 2014-12-03
AU2010225951B2 (en) 2014-03-13
JP4885308B2 (en) 2012-02-29
AU2010225951A1 (en) 2011-09-22
KR20110139745A (en) 2011-12-29
SG10201703707YA (en) 2017-06-29
JP2011173918A (en) 2011-09-08
RU2565809C2 (en) 2015-10-20
SG174428A1 (en) 2011-10-28
JP2012504106A (en) 2012-02-16
TWI440470B (en) 2014-06-11
JP5661553B2 (en) 2015-01-28
AR075908A1 (en) 2011-05-04

Similar Documents

Publication Publication Date Title
SG10201900451SA (en) Pharmaceutical formulation containing improved antibody molecules
MY153908A (en) Improved antibody molecules
NZ601114A (en) Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
GEP201706734B (en) FORMULATION FOR ANTI-α4β7 ANTIBODY
WO2008074997A8 (en) Pyridine benzamides and pyrazine benzamides used as pkd inhibitors
MX2013011366A (en) Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity.
GT201200069A (en) VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS
MX2011011772A (en) Stable high protein concentration formulations of human anti-tnf-alpha-antibodies.
MX2018005193A (en) Dual function proteins and pharmaceutical composition comprising same.
EP3351559A3 (en) Subcutaneously administered anti-il-6 receptor antibody
WO2011109365A3 (en) Concentrated protein formulations and uses thereof
WO2012006376A3 (en) Virion-like delivery particles for self-replicating rna molecules
WO2007092772A3 (en) Protein formulations
WO2013173129A3 (en) Treatment of amd using aav sflt-1
IN2014CN02591A (en)
WO2008103409A3 (en) Compositions of chloroquine coupled to antibodies and to other proteins with methods for their synthesis
DOP2010000379A (en) INSULIN COMPOUNDS LISPRO PEGILADA
WO2012151247A3 (en) FORMULATION FOR ANTI-α4β7 ANTIBODY
EP3207938A3 (en) Ctla-4 variants
WO2010078421A8 (en) Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds
WO2011098518A3 (en) Delivery of immunoglobulin variable domains and constructs thereof
WO2011086093A3 (en) Pharmaceutical compositions for oral administration of insulin peptides
JP6207291B2 (en) Composition for external use
MY184553A (en) Novel compounds as diacylglycerol acyltransferase inhibitors
BR112014017242A8 (en) immunogenic hpv l2-containing vlps and related compositions and methods